Biosergen (BIOSGN) Q2 2025 earnings summary

Executive summary

• Advanced BSG005 clinical program with manufacturing of a new GMP-compliant batch to support Cohort 3 and future phase 2/3 trials, maintaining regulatory progress in India and preparing for a U.S. IND application.

• Strengthened leadership with the appointment of a new CFO, Consultant Medical Lead, and a new Board member with significant anti-infective drug development experience.

• Strategic partnership with Alkem Laboratories continues, supporting clinical trials and future commercialization in India.

Financial highlights

• Q2 2025 operating loss was SEK 11.04 million, compared to SEK 16.2 million in Q2 2024.

• Net loss for the quarter was SEK 11.04 million, with earnings per share at SEK -0.05.

• Cash and cash equivalents at period end were SEK 33.3 million, up from SEK 12.2 million a year earlier.

• No new financing activities during the quarter; cash outflow from operations was SEK 11.5 million.

Outlook and guidance

• Priorities include completing BSG005 batch manufacturing, initiating Cohort 3, and advancing regulatory filings in India and the U.S.

• Continued focus on strategic partnerships and securing long-term capital resources.